Jaroslaw Maciejewski, MD, PhD

Appointed
2001

Education & Fellowships

Fellowship - National Heart, Lung and Blood Institute
Hematology
Bethesda, MD USA
2000

Residency - University of Nevada School of Medicine
Internal Medicine
Reno, NV USA
1998

Medical Education - Humboldt University Berlin, Medical School (Charite)
Immunology
Berlin,
1990

Medical Education - Humboldt University Berlin, Medical School (Charite)
Berlin,
1988

Professional Highlights

• Department Chair, Translational Hematology and Oncology Research
• Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Certifications

• Internal Medicine - Hematology

Specialty Interests

Bone marrow failure syndromes including aplastic anemia, myelodysplastic syndrome, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria, autoimmune neutropenia, pure red cell aplasia and other refractory anemias, cytopenias, acute lymphocytic leukemia

Awards & Honors

• America's Best Doctors

Memberships

• American Society of Clinical Investigation
• American Medical Association
• American Society of Hematology
• American Association of Physicians
• Member, Medical Advisory Board, Aplastic Anemia and MDS International Foundation
• Fellow in FACP since 7/1/09 from the Ohio Chapter 7/1/09
• American Society of Clinical Investigation

See publications for Jaroslaw Maciejewski, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/17/2022, Dr. Maciejewski has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Maciejewski receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Regeneron Pharmaceuticals, Inc.
• Celgene Corporation (a wholly-owned subsidiary of Bristol-Myers Squibb)
• Roche (Hoffman-La Roche, Ltd.)

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.